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Summary. A total of 53 patients with advanced lung 
cancer [non-small-cell (NSC), 21; small-cell (SC), 32] 
were treated with brequinar sodium. All of the NSC 
patients were chemotherapy-naive, but 31/32 (97%) SC 
patients had failed a multiagent chemotherapy program 
prior to study entry. Brequinar was given intravenously at 
a median weekly dose of 1200 mg/m2. The toxicity was 
moderate, with 19 patients (36%) experiencing grade 3 or 
4 toxicity. Objective responses were observed in one NSC 
and two SC patients. We conclude that at this dose and on 
this schedule, brequinar does not have sufficient activity in 
patients with NSC or in patients with previously treated SC 
to warrant further evaluation. However, since responses 
were observed in previously treated SC lUng-cancer 
patients, further evaluation in chemotherapy-naive patients 
may be warranted. 
Introduction 
Brequinar is a novel antimetabolite that interferes with 
dihydrooratate dehydrogenase, an enzyme crucial for py- 
rimidine biosynthesis [4]. Brequinar was selected for clini- 
cal development because of its broad antitumor activity in 
murine models (L1210 leukemia and B 16 melanoma) and 
human tumor xenografts [breast (MX- 1), colon (CX-1), 
lung (LX-1), and gastric (BL/STX-1)] [7]. 
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A number of phase I studies using different dose levels 
and schedules have been reported [1-3, 5, 8, 9]. In these 
phase I studies, the dose-limiting toxicities included 
thrombocytopenia and mucositis/stomatitis. On the basis 
of the phase I experience, the recommended phase II 
starting dose of brequinar on the weekly intravenous 
schedule was 1,800 mg/m 2 [2, 3]. However, early in the 
phase II evaluation of brequinar in several tumor catego- 
ries, this starting dose resulted in unacceptable toxicity [6]. 
As a result, the starting dose was reduced to 1,200 mg/m2 
weekly. This multicenter study was designed to evaluate 
the activity of brequinar in patients with advanced non- 
small-cell (NSC) and small-cell (SC) lung cancer. 
Patients and methods 
NSC patients were chemotherapy-naive and SC patients had received at 
most one prior chemotherapy regimen. Additional criteria for inclusion 
in the study were a performance status of --<2 (WHO scale), a life 
expectancy of >8 weeks, a serum bilirubin level of <1.5 mg/dl, a serum 
creatinine value of <2.0 mg/dl, an absolute granulocyte count of >1,500 
cells/mm 3, a platelet count of >100,000/mm 3, and the presence of bidi- 
mensionally measurable disease. Informed consent was given by all 
patients in accordance with regulatory agency requirements. 
Brequinar was given intravenously once weekly at a starting dose of 
1,800 (3 patients) or 1,200 mg/m 2 (50 patients) in 500 ml normal saline 
over 1 - 2  h. The subsequent dose of brequinar was escalated or 
decreased by a fixed amount as specified in the protocol according to 
predetermined criteria and depending on the toxicities experienced in the 
preceding course. When necessary, dosing was delayed until the patient 
had recovered from toxicities. Toxicity was coded by NCI common 
toxicity criteria (2/18/88 versions. 
Patients were interviewed and examined prior to each dose of chemo- 
therapy. Laboratory studies including complete blood cell. differential, 
and platelet counts were repeated once a week. Total protein, albumin, 
calcium, inorganic phosphorous, glucose, blood urea nitrogen, creat- 
inine, uric acid, total bilirubin, alkaline phosphatase, lactic dehydro- 
genase (LDH), and electrolytes were assessed every 4 weeks. 
Response was evaluated every 4 weeks by appropriate radiology 
studies and clinical measurement of bidimensional lesions. Criteria for 
defining response were standard except that a palpable reduction in liver 
size was not used to designate a partial response [10]. Patients were 
considered to be evaluable for response if they received at least one dose 
of brequinar and underwent a subsequent assessment of their measurable 
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Table 1. Patient and treatment characteristics 
Characteristics NSC SC 
Table 3. Toxicity encountered a 
Toxicity Number of patients by maximal grade 
Total patients 21 32 
(inevaluable/not eligible) (3/2) (1/0) 
Men: women 17/4 17/15 
Median age (range) 60 (39-77)  63 (41 -77)  
years years 
Performance statusa: 
0 2 10 
1 14 19 
2 5 3 
Sites of metastases: 
Liver 3(14%) 15(47%) 
Lung 13(61%) 18(56%) 
Lymph nodes 5(24%) 8(25%) 
Bone 4(19%) 5(16%) 
Skin/subcutaneous tissue 0(0) 4(12%) 
Other 5(24%) 9(28%) 
Prior therapy: 
Surgery/diagnostic procedure 11 14 
Radiation therapy 6 17 
Biological therapy 0 1 
Chemotherapy 0 31 
Baseline LDH: 
Mean/median 245/166 IU/1 418/245 IU/1 
a Worm Health Organization criteria [10] 
Table 2. Dosing and treatment results 
NSC SC 
Doses given: 
Total 152 191 
Median 7 4 
Range 1 - 24 1 - 20 
Median weekly dose 1,200 mg/m 2 1,200 mg/m 2 
(Range) (768- 2,986 mg/m 2) (740-1,500 mg/m 2) 
Number of patients: 
Dose escalation 8 3 
Dose reduction 6 11 
Receiving one dose only 1 2 
Treatment results: 
PR 1 2 
Stable disease 8 9 
Progressive disease 23 17 
disease. Patients who died of disease without undergoing such an assess- 
ment were considered to be evaluable and classified as having progres- 
sive disease. 
Results 
From January 1989 to July 1990, 53 patients with histo- 
logically or cytologically documented, advanced, measur- 
able carcinoma of the lung were entered in the study. 
Grade 1 Grade 2 Grade 3 Grade 4 
Anorexia 3 1 0 0 
Fatigue 5 2 1 0 
Nausea/vomiting 22 6 4 0 
Mucositis/stomatitis 14 9 2 0 
Rash 3 5 1 0 
Diarrhea 13 6 6 0 
Thrombocytopenia 9 9 3 7 
Anemia 1 14 6 3 
Leukopenia 12 4 1 2 
Granulocytopenia 5 9 2 1 
a All patients were evaluable for toxicity 
Patient and treatment characteristics are listed in Table 1. 
The patients had excellent performance status. Of the 32 
SC patients, 31 had previously received multiagent chemo, 
therapy; 25 (81%) of these 31 patients had shown a re- 
sponse [partial response (PR), 14; complete response (CR), 
11] to prior chemotherapy. Those patients who had 
achieved a CR to this prior therapy had been off treatment 
for a median of 167 days (mean, 210 days) prior to the 
initiation of brequinar treatment. The predominant sites of 
metastatic disease were the liver, lung, lymph nodes, and 
bone. 
The dosing and treatment results are presented in 
Table 2. The 53 patients received 343 doses of brequinar 
(median, 5; range, 1-24). In 11 patients dose escalation 
was possible, and in 17 patients dose reduction was re- 
quired; 3 patients received oniy 1 dose. The median 
weekly dose was 1,200 rag/m2. Of the 53 patients, 49 were 
evaluable for response. Two patients were deemed in- 
eligible: one due to the absence of a measurable lesion and 
the other due to a history of prior malignancy. In addition, 
two patients were inevaluable due to early non-disease-re- 
lated death and inability to obtain follow-up tumor 
measurements. PRs were observed in one NSC and two SC 
patients. 
All 53 patients were evaluable for toxicity. In general, 
the toxicity encountered in this phase II trial was moderate. 
The major nonhematologic and hematologic toxicities en- 
countered are listed in Table 3. There was no treatment-re- 
lated death. In all, 13 episodes of grade 4 toxicity occurred 
in 8 (15%) patients (NSC, 3; SC, 5). In one NSC patient the 
grade 4 toxicity was associated with the 1,800-mg/m 2 
starting dose; the remaining instances of grade 4 toxicity 
occurred in patients whose starting dose was 1,200 mg/m 2 
and generally occurred during the early treatment doses. 
Seven patients experienced grade 4 thrombocytopenia. 
Five of these patients received platelet transfusions and 
four showed evidence of bleeding; however, in only two 
patients was the bleeding sufficient to require replacement. 
The grade 3 toxicities summarized in Table 3 occurred in 
11 (21%) patients (NSC, 8; SC, 3). In two NSC patients 
who experienced grade 3 toxicity the starting dose was 
1,800 mg/m2; the remaining grade 3 toxicities occurred in 
patients whose starting dose was 1,200 mg/m 2. 
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Grade 3 - 4  toxicity was observed in all three patients 
entered at the initial starting dose of 1,800 mg/m 2. The 
reduction in the starting dose to 1,200 mg/m2 resulted 
in a more acceptable level of grade 3 - 4  toxicity 
(16/50 patients, 32%). Dose escalation was possible in 
21% (11/53) of patients; however, despite the reduction in 
the starting dose, a further dose reduction was required at 
some point in the course of treatment in 32% (17/53) of 
patients. The reduction in the starting dose followed by 
additional escalations and reductions based on individual 
patient tolerance account for the wide range (740- 
2,986 rag/m2) of weekly doses given to these patients with 
lung cancer. The dose given to SC patients was escalated 
less frequently than that given to NSC patients, and the SC 
patients required dose reduction more frequently. This var- 
iation in tolerance may in part reflect the greater hepatic 
involvement in the SC patient group as well as their prior 
exposure to chemotherapy. 
Discussion 
The response rate of 5% (one-sided 95% confidence limit, 
26%) obtained in NSC lung cancer and that of 6% (one- 
sided 95% confidence limit, 20%) obtained in SC lung 
cancer are disappointing. On the basis o f  these results, we 
conclude that at this dose and on this schedule, brequinar 
sodium does not have sufficient activity to warrant further 
evaluation in patients with advanced NSC or previously 
treated SC lung cancer. However, since responses were 
observed in previously treated SC lung-cancer patients, 
further evaluation in chemotherapy-naive patients may be 
warranted. 
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